Palvella Therapeutics Gains Strong Analyst Backing Following Merger Completion

The recently finalized merger between Pieris Pharmaceuticals and Palvella Therapeutics has generated significant optimism among market analysts, with several firms raising their price targets for the newly formed biotechnology company. Now trading on the Nasdaq under the ticker symbol PVLA, the combined entity has attracted substantial positive attention from financial researchers.

Palvella enters this new chapter with a solid financial foundation, holding approximately $80.5 million in liquid assets. This capital reserve is expected to fund operational expenses through the second half of 2027, providing crucial support for upcoming clinical development milestones. The company’s lead candidate, QTORIN Rapamycin, represents a patented anhydrous gel... Read more...